

## **Agenix Limited ACN 009 213 754**

### **Supplementary Prospectus**

#### **1. Introduction and Important Information**

---

This document is a supplementary prospectus under Section 719 (1A) of the Corporations Act 2001 (Cth) dated 1 August 2016. It is the first supplementary prospectus issued by Agenix Limited ACN 009 213 754 (**Agenix**) in relation to its Public Offer of up to 60,000,000 New Shares at an Offer Price of \$0.05 per New Share to raise \$3 million and separate offer totalling 109,600,000 Acquisition Shares to CCP shareholders in connection with the acquisition CCP Holdings Pty Ltd and Cold Chain Partners Pty Limited (collectively **CCP Group**). No funds will be raised from the Acquisition Offer. (**Supplementary Prospectus**).

This document supplements, and should be read together with the Prospectus lodged with the Australian Securities and Investments Commission (**ASIC**) by Agenix Limited on 30 June 2016 (**Prospectus**).

**This document is important and should be read in its entirety in conjunction with the Prospectus. If you are in any doubt as to the contents of this document, you should consult your financial or legal advisor.**

Terms used in this Supplementary Prospectus shall have the same meaning as ascribed to them in the Prospectus, unless otherwise indicated.

#### **2. Key Offer Statistics**

---

Details regarding the Key Offer Statistics are set out on page 10 and section 2.1 (page 35).

A new paragraph is to be included immediately before the tables set out on page 10 and section 2.1 respectively as follow:

The minimum subscription pursuant to the Public Offer is \$3 million.

The maximum subscription pursuant to the Public Offer is \$3 million.

In the event that the minimum subscription is not obtained the Company will repay all Application monies without interest in accordance with the Corporations Act.

In the event that applications received exceed the maximum subscription, the Company will allocate applications at the sole discretion of the Directors having regard to the need to obtain the shareholder spread as required by Chapters 1 and 2 of the ASX Listing Rules. The Company will repay excess Application monies without interest in accordance with the Corporations Act.

### **3. Chairman's Letter**

---

On page 13, paragraph 3 the chairman recommends that the document including risks be studied in its entirety and that potential investors seek professional advice before making an investment decision. The offer under this Prospectus is highly speculative. Details of all the risks are set out in section 2E and section 7. The primary key risks which are not exhaustive are:

- Completion and re-quotation (Refer page 22 and section 7.3 (a) and (b): Page 75); and
- Commercialisation risk.

In the event that Agenix does not raise the minimum and maximum of subscription and achieve the necessary spread of shareholders as determined by the ASX Listing Rules, the transaction will not complete and all monies will be repaid in accordance with the Corporations Act without interest.

At present 21 commercial trials are being undertaken in Australia, USA/Canada and the EU on a paid and unpaid basis. There is a risk that the CCP Solution will not be accepted to a level that it becomes commercially viable.

On page 13, paragraph 5 the Directors indicate they will subscribe for up to \$400,000 of New Shares. The following paragraph is added immediately following this statement:

The Directors are seeking approval to participate from Shareholders in respect of the Priority Offer pursuant to ASX Listing Rule 10.11. The Directors being Craig Chapman and Adam Gallagher and or their related entities will only participate in the offer if and only if there is a shortfall at the time the Offer is expected to close. Existing and prospective shareholders will be given priority. The extraordinary general meeting to approve all Conditional Resolutions was held on 29 July 2016 with all resolutions passed. The Offer was scheduled to close on 28 July 2016 however has been extended until 8 August 2016 and therefore the Directors, having obtained Shareholder approval, are able to participate in the Public Offer.

### **4. Risks**

---

On page 23 of the Prospectus (b) Protection of IP/IT the following is added immediately at the end of the first paragraph - The CCP Solution has in part been designed and built utilising open source software. It is therefore subject to the same risks as all other software which is based on the use of open source software.

### **5. Snapshot of Agenix Limited, CCP Group and the Combined Group post completion**

---

A new section to be included after the first paragraph in Section 1 of the Prospectus (page 14), Agenix provides the following information regarding the current status of each of Agenix and CCP Group and what the intentions of the combined group (including the Company and CCP Group) are after the completion of the Acquisition and Public Offer.

## **Agenix – current status**

Agenix's key assets are its Thromboview and DiagnostiQ projects and their associated intellectual property. Agenix continues to seek strategic partners for the development or divestment of these projects whilst being placed on hold with a view to cost minimisation.

Agenix has assessed the funds required to fully commercialise Thromboview and concluded that it was beyond the Company's existing financial capacity. The clinical trials conducted to date were undertaken in USA, Australia and Canada. Whilst we have an indicative cost to undertake Phase III trials, the actual costs cannot be ascertained until such time that an application is lodged with the US Food and Drug Administration for approval to conduct same which will determine amongst other things the size of the trial in terms of the number of tests and patients. Given the efflux of time since the previous trial was completed there may be a requirement to revalidate the existing data by conducting a further Phase II trial. The size and scope of the trials could vary from \$USD 5 million to \$USD 50 Million inclusive of manufacturing and study costs. If regulatory approval was granted further funds would be required to enable commercialisation. The patent runway is diminishing and is due to lapse in 2022. If a strategic partner cannot be engaged within the next 12 months, the Company will abandon this project.

Agenix holds a royalty free perpetual licence for DiagnostiQ human health application pursuant to the licence agreement with Tyrian Diagnostics Limited.

The DiagnostiQ platform comprises a patented disposable test device which can be used for various applications either alone or together with the DiagnostiQ Reader for various tests. In simple terms once the specific microarrays are developed they could provide a reliable indicator to health practitioners that further investigation is warranted.

If a strategic partner cannot be engaged within the next 12 months, the Company will abandon this project.

## **CCP Group – current status**

The CCP Group model is to derive recurring sales from customers by selling its solution in the form of a Software as a Service agreement. Its business to business hardware and software solution monitors critical control points.

The CCP Solution is "market ready" having been installed and tested in real commercial environments. There are currently 12 trials in Australia, 7 in the USA and 2 in Europe all of which commenced from December 2015 in what is commonly termed as a soft launch. These commercial trials were installed on either a free or paid basis.

The initial target market is the food supply chain with initial focus on the perishable food industries in Australia and North America with emphasis on temperature monitoring. The commercialisation path encompasses direct sales, resellers and online sales channels. In the cold chain – a term, which is universally used in the food industry to describe interdependent operations in the production, distribution, storage and retailing of chilled and frozen perishable foods – temperature is one of the most critical environmental factors underpinning integrity. The

Page 3 of 15

CCP Solution has the ability to also monitor other critical control points including humidity, CO<sub>2</sub>, pH, electricity and other ambient environmental considerations. The CCP Solution is primarily designed to operate in a fixed physical location; however, can be used in transport and logistics settings. The focus on temperature monitoring in the first instance is driven by two primary factors being:

- the requirement of businesses who deal with perishable foods to monitor and record temperatures pursuant to either local, state or federal legislative instruments; and
- the current costs to businesses who chose to adopt automated temperature monitoring systems.

The second market that CPP intends to address is the health market. This market contains well-established service providers with whom CPP intends to look to partner or possibly acquire to access this market. CCP Group will leverage the Company's experience with biologicals and the storage of same as biologicals are usually highly temperature dependant.

## 6. Capital Structure – post issue

Details of the capital structure of Agenix on completion of the issue and allotment of Shares pursuant to the Prospectus and completion of the Acquisition and details of the percentage interests held by various groups of Shareholders are set out in section 3.6 of the Prospectus.

The following table provides a further breakdown of the share interests of various groups of shareholders both on completion of the issue and allotment of Shares pursuant to the Prospectus and completion of the Acquisition, together with the dilutionary effect on the various groups of Shareholders should the Milestone Targets be achieved and the Milestone Shares be allotted. The following table is included as a new section at the bottom of the section titled "Key Offer Statistics" on page 10 of the Prospectus and should be read in conjunction with Section 3.6 of the Prospectus.

### Capital Structure on Completion

Shareholder	Number of Shares	%
Existing Shareholders <sup>1</sup>	31,445,161	15.49
Public Offer <sup>2</sup>	60,000,000	29.55
CCP Group Shareholders <sup>3,4,5</sup>	109,600,000	53.98
Advisor Shares <sup>3</sup>	2,000,000	0.98
<b>Total<sup>5</sup></b>	<b>203,045,161</b>	<b>100.00</b>

#### Notes:

1. Shareholder approval has been given in respect of the 5:1 Share Consolidation which is a Conditional Resolution.
2. Assumes the Public Offer is fully subscribed.
3. These securities may be subject to ASX escrow conditions governing their resale. See section 2.19 and 13.17 for further details.
4. This excludes Milestone Shares.
5. Assumes that no CCP Group Shareholders acquire New Shares under the Public Offer.

In addition, the Company has the ability, following Shareholder approval, to issue and allot up to a maximum of 2,500,000 Advisor Options. These options will have an exercise price of \$0.055 and expire 3 years from the date of the allotment. See section 12.7 for further details on the terms of the Advisor Options.

**Capital Structure assuming all Milestone Targets are achieved and Shares are issued on attaining those targets**

<b>Shareholder</b>	<b>Number of Shares</b>	<b>%</b>
Existing Shareholders <sup>1</sup>	31,445,161	14.63
Public Offer <sup>2</sup>	60,000,000	27.90
CCP Group Shareholders <sup>3,4,5</sup>	121,600,000	56.54
Advisor Shares <sup>3</sup>	2,000,000	0.93
<b>Total<sup>5</sup></b>	<b>203,045,161</b>	<b>100.00</b>

**Notes:**

1. Shareholder approval had been given in respect of the 5:1 Share Consolidation which was a Conditional Resolution.
2. Assumes the Public Offer is fully subscribed.
3. These securities may be subject to ASX escrow conditions governing their resale. See section 2.19 and 13.17 for further details.
4. This assumes the allotment of 12 million ordinary shares upon achieving all the Milestone Targets as set out in Section 13.6 of the Prospectus.
5. Assumes that no CCP Group Shareholders acquire New Shares under the Public Offer.

**Proposed Use of Funds and Offer and Acquisition Costs**

Details regarding the proposed use of funds raised from the Public Offer are set out on page 11 and in section 3.5 (planned expenditure page 50). Details regarding the Offer and Acquisition costs are set out in section 13.13 (page 145).

The following tables and information provides a more detailed breakdown of the proposed use of funds. The Prospectus is amended by deleting the section titled 'Proposed Use of Funds' on page 11 and replacing it with the following:

Pursuant to the Public Offer, Agenix will raise a minimum and maximum of \$3 Million. It is proposed these funds will be utilised as follows:

	<b>Subscription</b>		
	<b>Year 1</b>	<b>Year 2</b>	<b>Total</b>
<b>Sales and Business Development Costs</b>			
Business Development including USA expansion <sup>1</sup>	530,000	180,000	710,000
Sales and Marketing Activities <sup>2</sup>	80,000	80,000	160,000
<b>Research and development costs</b>			
Research and development <sup>3</sup>	450,000	100,000	550,000
<b>Administration and other expenses</b>			
Administration and other expenses <sup>4</sup>	300,000	300,000	600,000
<b>Employment costs</b>			
Employment costs of executive and administrative salaries <sup>5</sup>	310,000	400,000	710,000
<b>Offer and acquisition costs</b>			
Acquisition costs of CCP Group <sup>6</sup>	Nil	Nil	Nil
Expenses of the Offer <sup>7</sup>	270,000	Nil	270,000
<b>Total Expenditure</b>	<b>1,940,000</b>	<b>1,060,000</b>	<b>3,000,000</b>

**Notes:**

1. USA Business development costs includes business development salaries and USA expansion. This includes the proposed salary of the CEO.
2. Sales and Marketing Activities includes web based marketing campaigns and search engine optimisation
3. Research and development includes salaries related to those costs which will allow for the expansion of the types of monitoring to items such as but not limited to humidity, CO2, pH and other ambient environmental considerations together with development of interfaces required for the health industry.
4. General administrative overheads including but not limited to shareholder communications, insurances and registry and ASX fees.
5. Includes the proposed salary of COO and administration salaries.
6. Costs incurred in relation to the acquisition of CCP have been incurred or paid in full prior to the issue of the Prospectus and have been or will be settled with existing funds prior to completion.

7. Includes maximum fees of \$180,000 which has been allocated for payment to stockbrokers and financial advisors or the appointment of a manager during the offer period on appropriate commercial terms (Section 2.6 page 37). See table below for further details:

#### Offer and Acquisition costs

Item of Expenditure	Amount of expenditure (\$) (excluding GST)
ASX and ASIC fees	22,000
Legal and due diligence fees	86,000
Accounting	15,000
Advisor fees <sup>1</sup>	180,000
Printing and registry costs	30,000
<b>Estimate Total</b>	<b>333,000</b>
Amounts paid or to be paid from existing funds at the date of the Prospectus	63,000
Balance outstanding as at the date of the Prospectus	270,000

#### Note:

1. Assumes maximum fees of \$180,000 which has been allocated for payment to stockbrokers and financial advisors or the appointment of a manager during the offer period on appropriate commercial terms.

On completion of the Offer and the Acquisition the Company has budgeted to expend up to \$3 million over the next two years.

Notwithstanding the allocations set out above, in the event that the circumstances change or other beneficial opportunities arise, the Directors reserve the right to vary the proposed use of funds to maximise benefit to Shareholders.

#### 7. Further information on the CCP Solution and market opportunity

On page 59 of the Prospectus a case study is presented to show the financial effects on a food sector business should it be shown to have food safety issues. The case study shows the impact following an E Coli outbreak which occurred across 9 states in the USA. The strain of E Coli is known as Shiga toxin producing *E. coli* O26<sup>1</sup>. This strain is a reportable outbreak in accordance with US Laws<sup>2</sup>. This toxin can result in hemolytic uremic syndrome which may lead to permanent kidney damage or even death<sup>3</sup> with infants, the elderly and those with immune deficiency most at risk. Numerous studies have been undertaken on E Coli O26. It was demonstrated that the bacteria at 5°C with the middle and high concentrations O26 populations of the bacteria decreased more rapidly than at 15 and 25°C<sup>4</sup>. There is clear evidence that failure to store raw ingredients at recommended temperatures enables the bacteria to flourish. CCP Solution is

<sup>1</sup> <http://www.fda.gov/Food/RecallsOutbreaksEmergencies/Outbreaks/ucm470410.htm>


<sup>2</sup> <http://www.fda.gov/Food/GuidanceRegulation/FSMA/>

<sup>3</sup> <https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/haemolytic-uraemic-syndrome>

<sup>4</sup> <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC91700/>

designed to address, amongst other thing temperature control issues if temperature was in fact determined as the primary cause. A range of factors may have contributed to the decline in value of the shares.

In Section 5 of the Prospectus information is presented on the size of both the broader food market and health markets. They are relevant in that the CCP Solution can be applied across a range of sectors within these markets. A common term used in the food industry is “paddock to plate”. The diagram set out above and on page 66 of the Prospectus illustrates the important segments and stakeholders involved in the industry.



The items highlighted in the diagram represent the initial focus in respect of the CCP Solution. In respect of geographical terms, the Asia Pacific includes Australia. The CCP Solution can be utilised across all the application above, for all product and infrastructure types and by all stakeholders throughout all regions. The CCP business plan is to initially focus on the food sector (as outlined above) and then look to expand within the food sector whilst also extending sales and marketing efforts into the health sector. As stated on page 64 of the Prospectus, the health market contains well-established service providers offering data logging and temperature management and therefore it is expected that market penetration would take considerable time. The intent is to enter this market in partnership with and or through acquisition of existing service providers.

On page 63 of the Prospectus the references to the addressable market of 470 million monitoring points is based upon CCP’s internal research and assessment of the market.

On page 79 of the Prospectus we state that investments in early stage commercialisation technologies such as CCP Solution are often uncertain or unproven. Whilst the CCP Solution is commercially ready for market and trials undertaken to date have met or exceeded the expectations of the Directors, the CCP Solution is yet to have operated through its whole product lifecycle. The system is designed to operate for a period of two years under normal operating



circumstances. However, there are numerous variables which may impact on its performance including but not limited to the environment in which it operates and the frequency of reporting. Until such time as the system has been widely deployed in excess of the expected lifecycle it is extremely difficult to predict with certainty those factors that will impact upon its performance.

## **8. Statistical and other references**

---

The Prospectus contained various statistics regarding market sizes which CCP Group intends to target with its CCP Solution. The following are provided as references to those statistics:

1. **Section 5: Page 57:** The market for real time automated temperature is substantial and estimated to reach US\$1.22 billion in 2017: Source: <http://www.frost.com/prod/servlet/press-release.pag?docid=282785506>
2. **Section 5: Page 63:** The total value of the US Food Industry is about \$1.24 trillion annually: Source – US Department of Agriculture <http://www.ers.usda.gov/topics/food-markets-prices/food-service-industry/market-segments.aspx>.
3. **Section 5 Page 63:** the Australian food industry is valued at \$132 billion: Source: <http://www.agriculture.gov.au/SiteCollectionDocuments/ag-food/food/national-food-plan/submissions-received/foodmap-an-analysis-of-the-australian-food-supply-chain-30-july.pdf>.
4. **Section 5 Page 65:** Most food businesses continue to apply a manual approach to temperature monitoring due to the high cost of solution implementation. This statement is based upon the extensive knowledge of the cold chain industry of the CCP Directors who have been operating in the industry for in excess of 20 years.

The estimate of 470 million monitoring points (at set out on page 63 of the Prospectus) in the combined Australian and US food industry is calculated by CCP on the basis on its extensive knowledge of the cold chain industry, the market size and the average configurations adopted throughout the industry when designing and constructing coal chain facilities. When utilising the same knowledge and applying those parameters to the initial target market CCP has assessed that a combined serviceable addressable market of 2.8 million monitoring points.

For the purposes of food market value, the 2010 total retail food sales and the total food service sales figures estimated and released by the US Department of Agriculture (**USDA**) (Refer 1 above); noting the food marketing system, including food service and food retail, supplied about \$1.24 trillion worth of food. The USDA also states that of this total, \$594 billion was supplied by foodservice facilities (48%). Therefore, the food retail sector must account for approximately \$646 Billion or 52% being the two segments which make up this market.

In Australia, the food industry is valued at \$132 billion (Refer 2 above), which is made up of foodservice facilities at \$45 billion and food retail sector at \$87 billion. Therefore, the Australian foodservices sector accounts for approximately 34% of sales by value; and the US food market is therefore approximately 9.5 times larger by value than the Australian food market overall, but

importantly the foodservices sector is approximately 13 times larger by value than the Australian foodservices sector.

The above statistics clearly demonstrates that consumer spending on foodservice facilities in the USA is much higher than Australia and hence why CCP has chosen to target the US market.

No consent has been received for any statistical references either set out above or in the Prospectus. Agenix relies upon ASIC Corporations (Consents to Statements) Instrument 2016/72.

## **9. Patent**

---

Details of the patent pending are set out in Section 6.

The patent application has been lodged as an international patent. The patent is still subject to examination. Patent applications by their very nature are detailed and complex and there is a real possibility that the patent application as lodged may need to be amended to satisfy the requirement of the various patent offices where it is intended to be lodged. There is a risk that upon examination that the patent will be rejected based upon it not being inventive or that unknown prior art exists. The time required to obtain a patent can be extensive and as such technological developments may make the technology redundant prior to obtaining the patent. Whilst, the existence of a patent assisted Agenix in its determination it did not rely upon it as a factor upon which to base its decision to accept the offer from CCP Group Shareholders. Agenix preferred to rely upon the expertise of management, the commercial readiness of the CCP Solution and the trade secrets surrounding the CCP Solution.

The CCP Group hold an Australian registered trademark No 1658824 in respect of the CCP Solution smart tag logo. The Company will assess whether or not this trademark will continue to be used or if further logo's and or trademark protection should be initiated.

## **10. Financial Statements**

The Prospectus included a typographical error.

On page 96 item (f) should read Alignment of accounting policies to reflect the reverse acquisition accounting treatment of equity with the recognition as an expense of the \$1,233,093 being the deemed cost of acquisition in accordance with AASB 3.

The Pro Forma Statement of Financial Performance on page 97 of the Prospectus stated that the amount expensed to the Profit and Loss being the fair value of the listing costs of the CCP Acquisition amounted to \$1,260,593, the correct amount is \$1,233,093 which reconciles with the amount shown in Note 5 Accumulated Losses.

## **11. Material Contracts - Note Deed**

Details regarding the terms of the Note Deed are set out in section 12.5 (page 130) of the Prospectus.

A new paragraph to be included in section 12.5 (page 130) immediately after the heading '12.5 Note Deed'

The Company entered into the Note Deed with CCP Holdings Pty Limited on 2 February 2016. The entering into the Note Deed gave the Company exclusive rights to evaluate and undertake formal due diligence in respect of the CCP Group. The Note Deed provides that a maximum of \$250,000 would be advanced by way of monthly instalments during the formal due diligence period. The formal due diligence period of 50 days allowed the Company to verify matters already disclosed. The funds advanced allowed CCP Group to continue their commercialisation path with certainty that an amount of funding was available. The Note Deed provided that the Company was granted security of all the assets and undertakings of the CCP Group including but not limited to the intellectual property. Following completion of the formal due diligence, the Company advanced a further \$250,000 to bring the total loan to \$500,000 as per the Note Deed to allow CCP Group to continue its commercialisation. Assuming completion of the Acquisition the ultimate legal owner of the Note Deed will be the Company and it will become an intercompany loan, and will be eliminated on consolidation. In the event that Completion does not occur the loan will be repayable by way of equal monthly instalments of principal and interest over a 24-month period commencing on 8 August 2016.

### **New Section 10A – Reseller Agreements**

A section 10A is to be included immediately before the section 11 as follow:

The Company has entered into agreements with resellers to assist in the continued commercialisation of the CCP Solution. No single reseller agreement is considered material to the Company and the Company's intention is to ensure that there is no significant reliance upon an individual reseller.

The standard terms of the reseller agreements created by CCP Group provide the following key matters:

- (a) Non-exclusive rights to sell and market the CCP Solution in a predefined geographical territory;
- (b) Term of 1 year with automatic extensions of 1 year provided performance targets are met;
- (c) Pre-determined performance targets are set for the territory;
- (d) Quarterly reporting of performance;
- (e) Non-binding recommended pricing structure which complies with all relevant legislation in regards to pricing; and
- (f) Ability to use the CCP intellectual property.

CCP Group reserve the right to negotiate reseller agreements on an individual basis with each reseller who through normal commercial negotiations requires terms amended in respect of the CCP Standard reseller agreement.

## **12. Approval Conditions**

---

Details regarding the Approval Conditions are set out in the table in section 12.6 (pages 126 and 127).

References to the Company as set in the table (refer above) shall be amended as follows:

Condition A – delete the words “The Company” and replace with Agenix.

Condition B – delete all the words and replace with – Agenix completing a capital raising on terms satisfactory to Agenix.

Condition G – delete the words “The Company” and replace with Agenix.

Condition K – delete the words “The Company” and “the Company” and replace each with Agenix.

The following paragraph is included in the Prospectus immediately before (c) Consideration (page 127).

In the event that Agenix is unable to complete Conditions B, C, D and F, the SSA will be terminated and the Acquisition will not be completed. Should this occur Agenix will repay all Application monies without interest in accordance with the Corporations Act.

### **13. Approval Resolutions**

---

Details of the Approval Resolutions are set out in section 3.9 of the Prospectus. The Notice of Extraordinary General Meeting and Explanatory Memorandum was lodged with ASX and ASIC on 29 June 2016 and despatched to Shareholders on that date. The Extraordinary General Meeting was held at 11:30am on 29 July 2016.

The Notice of Extraordinary General Meeting and Explanatory Memorandum set out in detail the matters to be dealt with by Shareholders. The Company relies up the incorporation by reference provisions of the Corporations Act as the Company is a continuous disclosing entity in accordance with section 111AC of the Corporations Act.

Shareholders and prospective investors should read the Notice of Extraordinary General Meeting and Explanatory Memorandum in its entirety which is available on the Company’s website or ASX announcements for the Company.

The Company will provide a copy of the Notice of Extraordinary General Meeting and Explanatory Memorandum free of charge on request by contacting the Company by the means set out in the Corporate Directory of the Prospectus.

### **14. Additional Information relating to a Director – Craig Chapman**

---

A new paragraph to be included in the Prospectus in Section 10.1 - 1. Craig Chapman - immediately after the first paragraph.

In addition to the above Craig was appointed a Director and Chief Executive Officer of Octaviar Limited<sup>5</sup> at the request of Octaviar Limited shareholders. This appointment was for a period 43 days from 25 March 2008 to 7 May 2008. Craig’s role was to ascertain what action if any could be undertaken to rescue the company from the well-publicised financial difficulty it had found

---

<sup>5</sup> Octaviar Limited was previously known as MFS Limited and was a diversified ASX listed investment company.

itself in. Administrators and Receiver Managers were appointed in September 2008. Craig also acted as a non-executive director of Evolve Salons Limited from 11 October 2013 until 28 October 2015. A liquidator was appointed to Evolve Salons Limited on 7 December 2015.


## 15. Corporate Structure

---

Details of the corporate structure are set out in section 13.8 (page 140) of the Prospectus.


To assist users in understanding the tables set out in section 13.8 the following diagrams are provided:

### Agenix Limited Current Structure




All owned and controlled 100%

### CCP Group Structure



Cold Chain Partners Pty Limited and CCP Holdings Pty Limited are owned directly by CCP Shareholders. Cold Chain Partners Pty Ltd holds all intellectual property and licences it to CCP Holdings Pty Limited. All other companies owned and controlled 100% by CCP Holdings Pty Limited.

## Proposed Corporate Structure



All 100% owned and controlled

### 16. Closing Date of the Priority and Public Offers

In accordance with a resolution of the Directors of the Company dated 25 July 2016, the Priority Offer Closing Date under the Prospectus is extended from 5:00pm (Perth Time) Friday 22 July 2016 to **5:00pm (Perth Time) Monday 8 August 2016** and the Public Offer Closing Date is extended from 5:00pm (Perth Time) Thursday 28 July 2016 to **5:00pm (Perth Time) Monday 8 August 2016**, subject to the right of the Directors to close the Offers earlier or to extend the Closing Dates without notice (**Extended Notice**). The Directors continue to reserve the right to further extend the Priority Offer Closing Date for Priority Offer Application Forms, or to extend the Closing Date of the Public Offer or the Acquisition Offer Closing Dates under the Prospectus.

### Consequential Amendments to the Prospectus

As a consequence of the extension of the Priority Offer Closing Date and Public Offer Closing Date (as referred above) the Prospectus is to be amended as follows:

- (a) Page 9, Indicative Timetable – For the event “Priority Offer closes” the date “22 July 2016” is deleted and replaced with “8 August 2016” and for the event “Public Offer closes” the date “28 July 2016” is deleted and replaced with 8 August 2016;
- (b) Page 36, Section 2.2 Indicative Timetable – For the event “Priority Offer closes” the date “22 July 2016” is deleted and replaced with “8 August 2016” and for the event “Public Offer closes” the date “28 July 2016” is deleted and replaced with 8 August 2016;
- (c) Page 37, Section 12.7 When to Apply for Offer Shares – In reference to the Closing Date of the Offer the date “28 July 2016” is deleted and replaced with “8 August 2016”;
- (d) Page 40, Section 12.12 When to Apply for Offer Shares under the Priority Offer – In reference to the Closing Date of the Priority Offer the date “22 July 2016” is deleted and replaced with “8 August 2016”;
- (e) Page 151, Section 15 Glossary of defined terms – In the definition of Priority Offer Closing Date the date “22 July 2016” is deleted and replaced with “8 August 2016” and the

definition "Public Offer closes" the date "28 July 2016" is deleted and replaced with 8 August 2016;

## **17. Lodgement with ASIC**

---

A copy of this document was lodged with ASIC on 1 August 2016. This document will prevail to the extent of any inconsistency with the Prospectus lodged with ASIC on 30 June 2016. Neither ASIC nor any of its officers take any responsibility for the contents of this document.

## **18. Authorisation**

---

This Supplementary Prospectus has been approved by a resolution passed by the directors of Agenix Limited. Each Director and Proposed Director has consented in writing to lodgement of this Supplementary Prospectus with ASIC.

Dated 1 August 2016

Signed for and on behalf of Agenix Limited

A handwritten signature in black ink, appearing to read 'Craig Chapman', with a horizontal line extending to the left.

Craig Chapman

Director